Nancy U. Lin, MD, on the HER2CLIMB Trial: Triplet Regimen for Metastatic Breast Cancer

Posted: Friday, May 29, 2020

Nancy U. Lin, MD, of Dana-Farber Cancer Institute, talks about whether the positive results with tucatinib, trastuzumab, and capecitabine from the HER2CLIMB study of patients with previously treated HER2-positive metastatic breast cancer that had metastasized to the brain are expected to change clinical practice in the near future.